| Reviewer | Employment | Research Grant | Other Research Support | Speakers' Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| Colin Derdeyn | Washington University | None | Genentech* | None | Genentech* | nFocus* | WL Gore & Associates† | None |
| Philip Gorelick | University of Illinois | None | None | Boehringer-Ingelheim† | None | None | Genentech* | None |
| Pooja Khatri | University of Cincinnati | NIH K23† | None | None | None | None | None | None |
| Tanya Turan | Medical University of South Carolina | NIH/NINDS for SAMMPRIS, Director of Risk Factor Management† | AAN Foundation Clinical Research Training Fellowship† | None | Expert witness in medical malpractice stroke cases* | inme | inme | inme |
| This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. | ||||||||
| * Modest. | ||||||||
| † Significant. |